A High-Throughput Screen Identifies PARP1/2 Inhibitors as a Potential Therapy for ERCC1-deficient Non-Small Cell Lung Cancer

Oncogene - United Kingdom
doi 10.1038/onc.2013.311
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Identification of Withaferin a as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer

Cancers
Cancer ResearchOncology
2019English

ERCC1 and Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2010English

Plasma microRNAs as Potential Biomarkers for Non-Small-Cell Lung Cancer

Laboratory Investigation
Forensic MedicinePathologyCell BiologyMolecular Biology
2010English

Designing a Novel High-Throughput AlphaLISA Assay to Quantify Plasma NHERF1 as a Non-Small Cell Lung Cancer Biomarker

RSC Advances
ChemistryChemical Engineering
2015English

Hsa_circ_0033155: A Potential Novel Biomarker for Non‑small Cell Lung Cancer

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Hmgb1: A Potential Therapeutic Target for Non-Small Cell Lung Cancer

Lettters in Health & Biological Sciences
2016English

A Decade of Targeted Therapy for Non-Small Cell Lung Cancer

2017English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

Small-Molecule Collection and High-Throughput Colorimetric Assay to Identify PARP1 Inhibitors

Methods in Molecular Biology
GeneticsMolecular Biology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy